Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Orthofix (OFIX) Advances in ALIF Procedure With New Launch
by Zacks Equity Research
Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.
Quest Diagnostics (DGX) Partners to Offer New Testing Service
by Zacks Equity Research
Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.
Here's Why You Should Buy Boston Scientific (BSX) Stock
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement at the Animal Health segment.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?
by Zacks Equity Research
The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.
Hologic (HOLX) Gains From Core Businesses' Growth, Innovation
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care
by Zacks Equity Research
Surmodics' (SRDX) receipt of FDA's clearance is expected to expand the treatment range of the Pounce platform and serve a wider patient pool.
Cardinal Health (CAH) to Build Distribution Center in Greenville
by Zacks Equity Research
Cardinal Health's (CAH) new facility will be its largest at-Home Solutions distribution center that will support business growth by providing new space and automation.
CONMED (CNMD) Stock Hits 52-Week High: Will It Continue?
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism in investors due to its broad product spectrum.
IDEXX (IDXX) Launches First Veterinary Diagnostic Test
by Zacks Equity Research
IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.
3 Reasons to Hold Patterson Companies (PDCO) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
BD's (BDX) Latest Product to Automate Clinical Flow Cytometry
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) product is expected to lead to increased automation in clinical lab workflow.
Neogen (NEOG) Introduces Improved Genomic Test for Cats
by Zacks Equity Research
Neogen's (NEOG) My CatScan 2.0 offers insightful genetic information that enables preventive cat care by tackling curable conditions.
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.
Masimo (MASI) Inks Deals for Patient Monitoring Technologies
by Zacks Equity Research
Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.
NextGen (NXGN) Expands Partnership With Large Urology Group
by Zacks Equity Research
NextGen's (NXGN) cloud-based healthcare technology solution, Enterprise EHR, is selected by Associated Urologists of North Carolina to create an integrated platform, especially for urology-specific workflows.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Encompass Health's (EHC) 158th Hospital Opens in Maryland
by Zacks Equity Research
The Rehabilitation Hospital of Bowie is Encompass Health's (EHC) second location in the state of Maryland.
QIAGEN's (QGEN) QCI Is Used by Danish National Genome Center
by Zacks Equity Research
QIAGEN's (QGEN) QCI Interpret offers evidence-based variant interpretation and reporting, and upholds the highest standards for data security and privacy. It also provides testing sites flexibility.
Here's Why You Should Retain Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) on solid long-term growth potential in the oncology space.
CVS Heath (CVS) MinuteClinic Earns 6th Health Care Approval
by Zacks Equity Research
CVS Heath's (CVS) MinuteClinic has an in-clinic Net Promotor Score of more than 81, putting it in the top customer rankings.
Revvity (RVTY) Launches Single Solution for Drug Development
by Zacks Equity Research
Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.
Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.